Bevacizumab News and Research RSS Feed - Bevacizumab News and Research

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Study: Brain tumors hijack the brain's existing blood supply during progression

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time. [More]
Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population. [More]
Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. [More]
Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint. [More]
Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. [More]

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database. [More]
Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Cervical cancer affects approximately 500,000 women every year globally of which 250,000 die annually, making it the 2nd leading cause of cancer-related death in women. [More]
Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Research and Markets has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. [More]
Research report on China's bevacizumab market

Research report on China's bevacizumab market

Research and Markets has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering. [More]
Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Updated data from the phase III AVAPERL trial hint that there might be an overall survival benefit of using bevacizumab in combination with pemetrexed as maintenance therapy in patients with advanced nonsmall cell lung cancer. [More]
Study establishes innovative approaches to improve vision of young children with brain tumor

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor. [More]
Randomized trial of bevacizumab for glioblastoma shows disappointing results

Randomized trial of bevacizumab for glioblastoma shows disappointing results

"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival." [More]
Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA. [More]